Drug Shortage Report for SANDOZ REPAGLINIDE
Report ID | 136067 |
Drug Identification Number | 02357488 |
Brand name | SANDOZ REPAGLINIDE |
Common or Proper name | SANDOZ REPAGLINIDE |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | REPAGLINIDE |
Strength(s) | 2MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100TAB BO CA |
ATC code | A10BX |
ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-03-19 |
Estimated end date | 2021-04-30 |
Actual end date | 2021-04-30 |
Shortage status | Resolved |
Updated date | 2021-05-03 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2021-05-03 | French | Compare |
v5 | 2021-05-03 | English | Compare |
v4 | 2021-04-27 | French | Compare |
v3 | 2021-04-27 | English | Compare |
v2 | 2021-03-22 | French | Compare |
v1 | 2021-03-22 | English | Compare |
Showing 1 to 6 of 6